Cabozantinib for brain metastases in renal cell carcinoma: a single-institution retrospective analysis

Japanese Journal of Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 12, 2025

Abstract Objective Brain metastases from renal cell carcinoma (RCC) present considerable treatment challenges and poor prognoses. In this study, we evaluated the efficacy of cabozantinib, a multi- tyrosine kinase inhibitors (TKIs), in improving progression-free survival (PFS) overall (OS) patients with RCC brain metastases. Methods This retrospective study included 30 treated at single institution between 2010 2024. Patient demographics, modalities, outcomes were analyzed. Systemic therapies TKIs, immune checkpoint (ICIs). Local Gamma Knife surgery (GKS) whole-brain radiation therapy (WBRT). Survival using Kaplan–Meier analysis Cox proportional hazards models. Results Cabozantinib-treated (n = 12) exhibited significantly longer median PFS (21.6 vs. 4.1 months; P < .001) OS (25.7 8.3 .019) compared to non-cabozantinib 18). GKS, cabozantinib further improved (29.6 3.9 12.8 .001). regression identified as sole independent predictor (hazard ratio [HR], 0.09; .004) (HR, 0.17; .009). Conclusion Cabozantinib metastases, underscoring its role an effective systemic therapy. However, potential risks such hemorrhage highlight importance careful patient selection close monitoring. Further prospective studies are warranted explore optimal combination strategies.

Language: Английский

Predictive coding in the human olfactory system

Trends in Cognitive Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский